These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31091334)

  • 21. Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein.
    Chaurasia P; Nguyen THO; Rowntree LC; Juno JA; Wheatley AK; Kent SJ; Kedzierska K; Rossjohn J; Petersen J
    J Biol Chem; 2021 Sep; 297(3):101065. PubMed ID: 34384783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
    Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
    Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategic mutations in the class I major histocompatibility complex HLA-A2 independently affect both peptide binding and T cell receptor recognition.
    Baxter TK; Gagnon SJ; Davis-Harrison RL; Beck JC; Binz AK; Turner RV; Biddison WE; Baker BM
    J Biol Chem; 2004 Jul; 279(28):29175-84. PubMed ID: 15131131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes.
    Wucherpfennig KW; Hafler DA; Strominger JL
    Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8896-900. PubMed ID: 7568039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
    Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
    J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation and molecular recognition of melanoma-associated antigen-specific human γδ T cells.
    Benveniste PM; Roy S; Nakatsugawa M; Chen ELY; Nguyen L; Millar DG; Ohashi PS; Hirano N; Adams EJ; Zúñiga-Pflücker JC
    Sci Immunol; 2018 Dec; 3(30):. PubMed ID: 30552102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors.
    Wu D; Kolesnikov A; Yin R; Guest JD; Gowthaman R; Shmelev A; Serdyuk Y; Dianov DV; Efimov GA; Pierce BG; Mariuzza RA
    Nat Commun; 2022 Jan; 13(1):19. PubMed ID: 35013235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry.
    Merkle PS; Trabjerg E; Hongjian S; Ferber M; Cuendet MA; Jørgensen TJD; Luescher I; Irving M; Zoete V; Michielin O; Rand KD
    Biochemistry; 2021 Mar; 60(11):859-872. PubMed ID: 33689297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
    Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
    J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
    J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.
    Fleischhauer K; Tanzarella S; Wallny HJ; Bordignon C; Traversari C
    J Immunol; 1996 Jul; 157(2):787-97. PubMed ID: 8752930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational design of the affinity and specificity of a therapeutic T cell receptor.
    Pierce BG; Hellman LM; Hossain M; Singh NK; Vander Kooi CW; Weng Z; Baker BM
    PLoS Comput Biol; 2014 Feb; 10(2):e1003478. PubMed ID: 24550723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.
    Lai J; Wang Y; Wu SS; Ding D; Sun ZY; Zhang Y; Zhou J; Zhou Z; Xu YC; Pan LQ; Chen SQ
    Biomaterials; 2018 Sep; 178():158-169. PubMed ID: 29933102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures.
    Hausmann S; Biddison WE; Smith KJ; Ding YH; Garboczi DN; Utz U; Wiley DC; Wucherpfennig KW
    J Immunol; 1999 May; 162(9):5389-97. PubMed ID: 10228016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.
    Gervois N; Guilloux Y; Diez E; Jotereau F
    J Exp Med; 1996 May; 183(5):2403-7. PubMed ID: 8642353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.